myr-BRC4

myr-BRC4 is a **myristoylated cell-penetrating peptide** derived from the BRC4 repeat of **BRCA2**, developed as a research-stage **RAD51-BRCA2 interaction disruptor**. The peptide is designed to enter cells more efficiently than unmodified BRC4 and to bind RAD51, thereby impairing BRCA2-mediated RAD51 filament regulation and suppressing **homologous recombination DNA repair**. In published in vitro work, myr-BRC4 has been used to sensitize cancer cells to **PARP inhibition** and to model a synthetic lethality strategy in **BRCA-competent, olaparib-resistant pancreatic cancer** and related experimental systems. It is not an approved medicine and appears to be a preclinical laboratory tool rather than a clinically developed therapeutic product.

Other names

myristoylated BRC4 peptidemyristoylated derivative of BRC4